Welcome to our dedicated page for Alimera Sciences news (Ticker: ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.
Alimera Sciences, Inc. (NASDAQ: ALIM) is a leading global pharmaceutical company committed to advancing retinal health. Founded in June 2003, the company specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. Alimera's primary focus is on diseases affecting the retina, particularly those that are not well managed by current therapies. The company's flagship product, ILUVIEN, is a sustained-release intravitreal implant used for the treatment of diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) outside the U.S.
ILUVIEN utilizes CONTINUOUS MICRODOSING™ technology, releasing sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months. This technology helps to reduce disease recurrence, thereby enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S. and multiple international markets, including 17 European countries, China, and regions in the Middle East.
Recently, Alimera announced positive data from several clinical studies, such as the PALADIN study, which evaluated the long-term safety of ILUVIEN in treating DME. The company also made headlines by completing enrollment for the Synchronicity Study, focusing on YUTIQ, another fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis.
Moreover, Alimera continues to expand its executive team to strengthen its financial and operational capabilities. Elliot Maltz, C.P.A., has been named as the new Chief Financial Officer to drive growth and improve cash flow. The company's European operations are managed through its subsidiary, Alimera Sciences Limited, based in London.
Financially, Alimera Sciences has shown robust growth. In Q4 2023, the company reported net revenues of $26.3 million, an 88% increase compared to the same period in 2022. For the full year 2023, net revenues were up 49% to $80.8 million. This growth is a testament to the successful commercialization of ILUVIEN and YUTIQ.
Looking ahead, Alimera aims to further its mission of being invaluable to patients, physicians, and partners concerned with retinal health. The company is actively involved in numerous clinical studies and regulatory efforts to expand the therapeutic indications for its products, ensuring continued innovation and improved patient outcomes.
For more information, please visit www.alimerasciences.com.
Alimera Sciences announced that data on its product ILUVIEN® will be presented at the American Society of Retina Specialists (ASRS) conference from July 13-16, 2022. Key presentations include two specific studies on the outcomes of ILUVIEN in treating diabetic macular edema (DME), highlighting its effectiveness and treatment burden. The PALADIN study, which enrolled 202 eyes, confirms the benefits of prior corticosteroid treatment to manage intraocular pressure. ILUVIEN is a sustained-release implant aimed at reducing vision loss related to DME.
Alimera Sciences announces the approval of ILUVIEN for treating non-infectious uveitis affecting the posterior segment in Italy, with pricing and reimbursement confirmed by the Italian Medicines Agency (AIFA). This new indication aims to reduce uveitis recurrence and is set to launch with distribution partner SIFI. ILUVIEN utilizes CONTINUOUS MICRODOSING™ technology, allowing sustained release for 36 months. The launch marks an expansion as Italy becomes the fifth market for ILUVIEN's new indication, enhancing patient care in managing this chronic eye condition.
Alimera Sciences (Nasdaq: ALIM) announced that its partner, Ocumension Therapeutics, received approval from the National Medical Products Administration for an IND application to initiate a Phase III clinical study of fluocinolone acetonide intravitreal implant. This study aims to support marketing approval in mainland China for treating diabetic macular edema. The trial is designed to align with Alimera’s existing U.S. indication, targeting patients previously treated with corticosteroids who did not experience significant intraocular pressure increases. Alimera's leadership expresses excitement about this development.
Alimera Sciences (Nasdaq: ALIM) announced that President and CEO Rick Eiswirth will present a corporate overview at the LD Micro Invitational XII Conference on June 7, 2022, at 9:30am PDT. The conference will take place from June 7 to 9, 2022, at the Four Seasons in Westlake Village, CA. Mr. Eiswirth will also be available for one-on-one meetings with registered attendees. Alimera is committed to improving retinal health and enhancing vision for patients and their healthcare partners.
Alimera Sciences (Nasdaq: ALIM) announced positive findings from the phase 4 PALADIN study, presented at the ARVO conference on May 12, 2022. The study demonstrated that prior corticosteroid treatment significantly predicts intraocular pressure (IOP) response after ILUVIEN. The data suggests that ILUVIEN, a 0.19-mg fluocinolone acetonide implant, effectively mitigates the risk of uncontrolled IOP elevation in diabetic macular edema (DME) patients. Over 96% of treated eyes maintained a mean IOP ≤ 25 mmHg over 36 months, supporting ILUVIEN's long-term safety and efficacy.
Alimera Sciences (Nasdaq: ALIM) reported a consolidated net revenue of approximately $11.9 million for Q1 2022, up 6% from Q1 2021. U.S. net revenue rose 23% to $6.9 million, driven by a 25% increase in end user demand. However, international net revenue declined 11% to $5.0 million, primarily due to COVID-19 restrictions and unfavorable foreign exchange rates. Operating expenses grew to $14.4 million, leading to a net loss of $(6.0 million). Cash reserves fell to approximately $9.9 million as of March 31, 2022. The company will discuss these results on a conference call on May 9, 2022.
Alimera Sciences (Nasdaq: ALIM) will report its first quarter financial results on May 9, 2022, before the market opens. A conference call is scheduled for 9:00 AM ET the same day to discuss these results and provide updates on corporate developments. Registered participants will receive a dial-in number, and the call will be accessible via a live webcast. A replay will be available for a limited time after the call. Alimera focuses on retinal health and improving vision for patients.
Alimera Sciences announced the presentation of ILUVIEN® PALADIN data at the upcoming ARVO conference in Denver, Colorado from May 1-4, 2022. Key highlights will include a presentation on May 2 regarding three-year outcomes from the PALADIN Phase IV Study, assessing the predictive value of prior steroid challenge. Additionally, poster sessions will cover the distribution of intraocular pressure outcomes and the safety and effectiveness of the fluocinolone acetonide intravitreal implant from the European IRISS registry study. These studies aim to confirm ILUVIEN's benefits for patients with diabetic macular edema.
Alimera Sciences (Nasdaq: ALIM) announced the launch of its new corporate branding and relocation of its global headquarters to a modern facility in Forsyth County, Georgia. This marks the first rebranding in two decades, introducing a new logo and tagline, "We see more, together," aimed at emphasizing the company's commitment to improved retinal health solutions. The new headquarters promotes a collaborative environment with various workspace options. The CEO highlighted a refined focus on serving the retina community and the intention for continued global growth.
Alimera Sciences (Nasdaq: ALIM) will present a corporate overview at the virtual Q1 Investor Summit Conference on March 9, 2022, at 8:45 AM ET. Rick Eiswirth, President and CEO, along with CFO Phil Jones, will be available for one-on-one investor meetings on the same day. This event highlights Alimera's commitment to partnering with patients and physicians to enhance retinal health and vision longevity. For more information and registration details, visit Alimera's official site.
FAQ
What is the current stock price of Alimera Sciences (ALIM)?
What is the market cap of Alimera Sciences (ALIM)?
What is Alimera Sciences, Inc. specialized in?
What is ILUVIEN?
Where is Alimera Sciences headquartered?
What are the latest financial results for Alimera Sciences?
Who is the new Chief Financial Officer of Alimera Sciences?
What recent clinical studies has Alimera Sciences completed?
In which regions is ILUVIEN approved?
What is the mission of Alimera Sciences?
What technology does ILUVIEN utilize?
Where can I find more information about Alimera Sciences?
